Virus injected into tumors shows promise in early breast cancer safety trial
NCT ID NCT05376527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a modified vaccinia virus (VV-GMCSF-Lact) injected directly into tumors of 34 women with recurrent or metastatic breast cancer that no longer responded to standard treatments. The main goal was to check safety and find the highest safe dose. Researchers monitored side effects, virus levels in blood, and any tumor response. Because this is a Phase 1 study, it focuses on safety, not on curing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modified vaccinia virus (VV-GMCSF-Lact) injected into tumors
What this could lead to
If successful, this could point toward a new treatment option for hard-to-treat metastatic breast cancer by using a virus to attack tumors from within.
What could go wrong
This is a very early Phase 1 safety trial with only 34 people. It is designed to find safe doses, not to prove effectiveness. The virus may cause side effects like fever or liver issues, and it may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLYTIC VIROTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Moscow, Russia, 115478, Russia
-
N.N. Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia, 197758, Russia
-
National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation
Obninsk, Russia, 249036, Russia
-
Oncology Research Center, LLC
Saint Petersburg, Russia, 197758, Russia